AIM: To determine the outcome of patients that underwent liver resection for metastases from uveal melanoma. METHODS: Over a 9-year period, patients referred with uveal melanoma metastases were included. Following treatment of primary uveal melanoma, high-risk patients were offered to be enrolled into a 6-monthly non-contrast liver magnetic resonance imaging (MRI) surveillance. Following detection of liver metastases, patients were staged with a contrast-enhanced (Primovist(®)) liver MRI, computer tomography (CT) of the thorax and staging laparoscopy. RESULTS: 155 patients were referred with uveal melanoma liver metastases, of which 17 (11.0%) patients had liver resection and one patient was treated with percutaneous radio-frequency ablation. The majority of patients undergoing liver resection were treated with multiple metastectomies (n = 8) and three patients had major liver resections. The overall median survival for patients treated with surgery/ablation was 27 (14-90) months, and this was significantly better compared to patients treated palliatively [median = 8(1-30) months, P < 0.001]. Following surgery, 11 patients had recurrent disease [median = 13(6-36) months]. Patients who had undergone a major liver resection had a significantly poorer disease-free survival (P = 0.037). CONCLUSIONS: Patients who can undergo surgical resection for metastatic uveal melanoma have a more favorable survival compared to those who do not.
AIM: To determine the outcome of patients that underwent liver resection for metastases from uveal melanoma. METHODS: Over a 9-year period, patients referred with uveal melanoma metastases were included. Following treatment of primary uveal melanoma, high-risk patients were offered to be enrolled into a 6-monthly non-contrast liver magnetic resonance imaging (MRI) surveillance. Following detection of liver metastases, patients were staged with a contrast-enhanced (Primovist(®)) liver MRI, computer tomography (CT) of the thorax and staging laparoscopy. RESULTS: 155 patients were referred with uveal melanoma liver metastases, of which 17 (11.0%) patients had liver resection and one patient was treated with percutaneous radio-frequency ablation. The majority of patients undergoing liver resection were treated with multiple metastectomies (n = 8) and three patients had major liver resections. The overall median survival for patients treated with surgery/ablation was 27 (14-90) months, and this was significantly better compared to patients treated palliatively [median = 8(1-30) months, P < 0.001]. Following surgery, 11 patients had recurrent disease [median = 13(6-36) months]. Patients who had undergone a major liver resection had a significantly poorer disease-free survival (P = 0.037). CONCLUSIONS:Patients who can undergo surgical resection for metastatic uveal melanoma have a more favorable survival compared to those who do not.
Authors: E Weis; T G Salopek; J G McKinnon; M P Larocque; C Temple-Oberle; T Cheng; J McWhae; R Sloboda; M Shea-Budgell Journal: Curr Oncol Date: 2016-02-18 Impact factor: 3.677
Authors: Thomas M Aaberg; Kyle R Covington; Tony Tsai; Yevgeniy Shildkrot; Kristen M Plasseraud; Katherina M Alsina; Kristen M Oelschlager; Federico A Monzon Journal: Ocul Oncol Pathol Date: 2020-07-06
Authors: Marybeth S Hughes; Jonathan Zager; Mark Faries; H Richard Alexander; Richard E Royal; Bradford Wood; Junsung Choi; Kevin McCluskey; Eric Whitman; Sanjiv Agarwala; Gary Siskin; Charles Nutting; Mary Ann Toomey; Carole Webb; Tatiana Beresnev; James F Pingpank Journal: Ann Surg Oncol Date: 2015-11-23 Impact factor: 5.344
Authors: Rumana N Hussain; Sarah E Coupland; Helen Kalirai; Azzam F G Taktak; Antonio Eleuteri; Bertil E Damato; Carl Groenewald; Heinrich Heimann Journal: Cancers (Basel) Date: 2021-05-08 Impact factor: 6.639